Motus GI to Present at the Virtual Investor Fireside Chat Series
Rhea-AI Summary
Motus GI Holdings, Inc. (NASDAQ: MOTS) will present at the Virtual Investor Fireside Chat Series on June 15, 2020, at 2:00 PM ET. Timothy P. Moran, CEO, will discuss the company’s endoscopy solutions aimed at improving gastrointestinal diagnosis. The session includes a live Q&A, allowing real-time engagement with participants. A replay will be available after the event. The company’s flagship product, the Pure-Vu® System, enhances colonoscopy procedures, aiming to improve patient outcomes and reduce costs for hospitals. More information can be found on the company’s website.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, MOTS declined 11.67%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
FORT LAUDERDALE, Fla., June 11, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that Timothy P. Moran, Chief Executive Officer of Motus GI, will present at the Virtual Investor Fireside Chat Series on Monday, June 15, 2020, at 2:00 PM ET.
A live video webcast of the fireside chat will be available on the Events page of the Investors section of the Company’s website (www.motusgi.com). Immediately following the fireside chat, management will participate in an interactive Q&A session with interested parties, allowing participants to type in questions and receive live responses. A webcast replay will be available two hours following the live presentation and will be accessible for one year.
In addition to the fireside chat, management will be available for one-on-one calls with qualified members of the investment community. To schedule a one-on-one call, please submit a request through the conference website vifiresidechat.com, or contact the conference at info@virtualinvestorco.com. For more information about the event, please visit vifiresidechat.com.
About Motus GI and the Pure-Vu® System
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions. The Company’s flagship product is the Pure-Vu® System, a U.S. FDA cleared and CE Mark approved medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to improve visualization during a colonoscopy while preserving established procedural workflow by irrigating the colon and evacuating debris to provide a better quality exam. Challenges with bowel preparation for inpatient colonoscopy represent a significant area of unmet need that directly affects clinical outcomes and increases the cost of care in a market segment that comprises approximately 1.5 million annual procedures in the U.S. and approximately 4 million annual procedures worldwide. Motus GI believes the Pure-Vu® System may improve outcomes and lower costs for hospitals by reducing the time to successful colonoscopy, minimizing delayed and incomplete procedures, and enhancing the quality of an exam. In clinical studies to date, the Pure-Vu® System significantly increased the number of patients with an adequate cleansing level, according to the Boston Bowel Preparation Scale Score, a validated assessment instrument.
For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements. Forward-looking statements are based on the Company's current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms, including without limitation, risks related to the Company’s cost reduction plan, the cost savings and the cash expenses related to the implementation of the plan, risks related to the continued impact of the COVID-19 pandemic, risks inherent in the development and commercialization of potential products, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company’s Form 10-K filed on March 30, 2020, and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contact:
Bob Yedid
LifeSci Advisors
(646) 597-6989
bob@lifesciadvisors.com
FAQ
When will Motus GI present at the Virtual Investor Fireside Chat Series?
Who is presenting for Motus GI at the fireside chat?
What is the focus of Motus GI's presentation?
Will there be a Q&A session during Motus GI's presentation?
How can I access the webcast of Motus GI's presentation?
What is the Pure-Vu® System by Motus GI?
